Overview

The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

Status:
Not yet recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the predictive value of TMPRSS2-ERG gene fusion in patients with prostate cancer treated with radiation and hormonal therapy.
Details
Lead Sponsor:
Sir Mortimer B. Davis - Jewish General Hospital
Treatments:
Triptorelin Pamoate